SKY-0515, developed by Skyhawk Therapeutics, is an oral drug taken as a once-daily pill that works by targeting the genetic ...

AMT-130 is a gene therapy designed to lower levels of the huntingtin protein in the brain. It uses a harmless virus package, called an adeno-associated virus (AAV), to contain microRNA – genetic ...

8 min read | February 2026 HD research recap: published trial data from branaplam trial; new insights into the genetics of the HD “grey zone”; plus worms, brain circuits, eye tracking, and the hidden ...

A new review from the University of Cambridge explores ocular biomarkers in HD, including retinal scans and eye movement tracking.

The most complex computer in the world is not made of microchips – it’s sitting right inside your head. Although the fastest supercomputers rival the human brain for raw computational power, nothing ...

Imagine walking down your street on a bright, sunny morning when you stumble on the curb. It was only a small trip, nothing serious. You laugh it off and keep walking. But in the back of your mind, a ...

The results of a clinical trial, called VIBRANT-HD, investigating an oral drug designed to lower huntingtin (HTT) protein have now been published in Nature Medicine. This study found that the drug ...

For individuals in the HD “grey zone” between 36-39 repeats, an understanding of when symptoms may arise and what kind of symptoms is critical. A new study sheds light on different sequence patterns ...

In plain language. Written by scientists. For the global HD community.

Huntington’s disease (HD) is a fatal brain disorder caused by a defect in the huntingtin (HTT) gene, which produces an extra-long protein. This defect causes the HTT protein to form harmful clumps, or ...